XORTX Therapeutics (XRTX) Net Cash Flow (2022)

XORTX Therapeutics' (XRTX) quarterly Net Cash Flow came in at -$9.6 million in Q4 2022, down 767.63% on a QoQ basis from $1.4 million in Q3 2022.

XORTX Therapeutics (XRTX) Net Cash Flow (2022) Analysis & Trends

XORTX Therapeutics (XRTX) has 1 years of Net Cash Flow data on file, last reported at -$9.6 million in Q4 2022.

Quarterly Net Cash Flow changed N/A year-over-year to -$9.6 million in Q4 2022, while the trailing twelve-month figure through Sep 2023 was -$9.6 million (down 767.63% YoY) and the FY2025 annual result came in at -$1.6 million, down 74.42% from the prior year.
Net Cash Flow eased to -$9.6 million in Q4 2022, from $1.4 million in the prior quarter.
In the past five years, Net Cash Flow ranged from a high of $1.4 million in Q3 2022 to a low of -$9.6 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Cash Flow (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	652.90 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	-504.30 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-183.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	407.41 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-496,000.00
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-37.14 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	225.59 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-2.83 Bn
10	XORTX Therapeutics	2.78 Mn	2.78 Mn	-	-

Download Data